ArticleBiomedical chromatography : BMC2026
An Integrated Strategy for Decoding Bioactive Components and Mechanism of Jingtong Granules: Chemical Characterization, Network Analysis, Pharmacokinetic and Pharmacodynamic Studies.
Article in Biomedical chromatography : BMC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
This study aimed to identify bioactive constituents of Jingtong Granules (JTG), a traditional Chinese medicine for cervical spondylotic radiculopathy (CSR), characterize their in vivo exposure, and explore pharmacological targets and pathways. Chemical constituents were characterized by LC-MS with GNPS-based molecular networking, and key compounds were prioritized via molecular docking; pharmacokinetic analysis was characterized in vivo exposure, and anti-inflammatory activity was evaluated via NO production in LPS-stimulated BV2 cells. Network pharmacology with GO and KEGG enrichment identified potential targets and pathways. Seventy-three components were identified in vitro and 10 in vivo. Albiflorin, puerarin, and ginsenoside Rg1 were rapidly absorbed and reduced NO production dose-dependently. Network analysis suggested MMP9 and PTGS2 as key targets, involving TNF and PI3K-AKT signaling pathways. JTG and its exposed constituents exert anti-inflammatory effects by modulating inflammatory targets and pathways. Albiflorin, puerarin, and ginsenoside Rg1 are prioritized as candidate bioactive constituents; MMP9, PTGS2, TNF, and PI3K-AKT pathways are putative mechanistic nodes requiring further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.